Researchers identify Rb1 as a predictive biomarker for a new therapeutic strategy in some breast cancers
Preclinical study identifies Rb1 deficiency as key therapeutic vulnerability in a subset of breast cancers resistant to standard CDK4/6 inhibitors
Drugs that may exploit this vulnerability are already in clinical trials
Rb1-deficient cancers represent nearly 40% of triple-negative and estrogen receptor–positive tumors, which together account for roughly 20% of all breast cancers
Rb1 status could also serve as an important predictive biomarker...
Proton therapy shows survival benefit in Phase III trial for patients with head and neck cancers
At five years, 90.9% of proton patients were alive compared to 81% with traditional radiation
Proton therapy also showed benefits in quality...
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid...
ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after treatment as those who never received a vaccine
These findings have prompted a randomized Phase III trial to determine if mRNA COVID vaccines should be part of the standard of care for this type of therapy
If validated, findings could significantly increase the number of patients who benefit from...
New computational method improves ability to detect precancerous tissues
CoCo-ST is a novel method of mapping tissues that is superior to current state-of-the-art benchmarks in preclinical models
Technique allows...
ASTRO 2025: At 10 years, SBRT comparable to surgery for early-stage lung cancer
Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small...
MD Anderson experts highlight top trends ahead of 2025 ASTRO meeting
Major themes include advances in actionable biomarkers in pancreatic cancer, proton therapy, artificial intelligence and theranostics
MD Anderson...
Researchers identify new approach to overcome resistance to KRAS-targeted therapies
Many cancers with KRAS mutations, the most commonly mutated oncogene, develop rapid resistance to targeted therapy with KRAS inhibitors. A...
Machine learning model improves treatment selection in non-small cell lung cancer
A significant challenge in developing treatment plans for patients with metastatic non-small cell lung cancer (NSCLC) is deciding whether...